2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
OH W, McDERMOTT D, PORTA C, LEVY A, ELAIDI R, SCOTTE F, HAWKINS R, CASTELLANO D, BELLMUNT J, RHA S, SUN J, NATHAN P, FEINBERG B, SCOTT J, McDERMOTT R, AHN J, WAGSTAFF J, CHANG Y, OU Y, DONNELLAN P, HUANG C, McCAFFREY J, CHIANG P, CHUANG C, KORVES C, NEARY M, DIAZ J, MEHMUD F, DUH M. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review. International Journal Of Oncology 2013, 44: 5-16. PMID: 24247547, PMCID: PMC3867384, DOI: 10.3892/ijo.2013.2181.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedAsiaBevacizumabCarcinoma, Renal CellDrug-Related Side Effects and Adverse ReactionsEuropeFemaleHumansIndolesKaplan-Meier EstimateMaleMiddle AgedNiacinamidePhenylurea CompoundsPyrrolesSorafenibSunitinibTreatment OutcomeUnited StatesConceptsBevacizumab patientsAdverse eventsTreatment modificationTreatment patternsTreatment durationGrade 3/4 adverse eventsAdvanced renal cell carcinomaSafety of sunitinibMedian treatment durationAdvanced RCC patientsFirst-line treatmentAngiogenesis inhibitor therapyKaplan-Meier analysisRenal cell carcinomaTertiary oncology centerAssociated with higher ratesMedical chart reviewCommunity oncology clinicsAdvanced RCCInhibitor therapyTreatment discontinuationDose reductionCell carcinomaRCC patientsBevacizumab
2010
Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study
Choueiri T, McDermott D, Duh M, Sarda S, Neary M, Oh W. Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: Results from a medical chart review study. Urologic Oncology Seminars And Original Investigations 2010, 30: 848-855. PMID: 20926319, DOI: 10.1016/j.urolonc.2010.07.009.Peer-Reviewed Original ResearchConceptsPer-patient-per-monthPer-patient-per-month costsAngiogenesis inhibitorsMRCC patientsMetastatic renal cell carcinomaMedical chart review studyMedian treatment durationAngiogenesis inhibitor therapyRetrospective chart reviewRenal cell carcinomaTertiary oncology centerChart review studyDaily oral dosageResource utilization dataBev-S patientsInhibitor therapyCell carcinomaTreatment courseChart reviewAverage doseMedical chartsER visit costsOncology centersTreatment durationOral dosageAngiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review
Choueiri T, Duh M, Clement J, Brick A, Rogers M, Kwabi C, Shah K, Percy A, Antràs L, Jayawant S, Chen K, Wang S, Luka A, Neary M, McDermott D, Oh W. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice‐based on medical chart review. BJU International 2010, 105: 1247-1254. PMID: 19863525, DOI: 10.1111/j.1464-410x.2009.08972.x.Peer-Reviewed Original ResearchConceptsMetastatic renal cell carcinomaRenal cell carcinomaAnti-angiogenic agentsAdverse eventsCell carcinomaTreatment patternsTreatment modificationDiscontinuation due to adverse eventsIntravenous administration of bevacizumabResponse rateAdministration of bevacizumabCommon adverse eventsMedian treatment durationRate of adverse eventsMetastasis to boneAngiogenesis inhibitor therapyBetter-tolerated therapiesAnti-angiogenic treatmentMedical chart reviewTertiary oncology centreDose interruptionClinical practice settingInhibitor therapyDose reductionDiscontinued treatment
2008
Dosing and switching patterns for renal cell carcinoma (RCC) patients receiving selected angiogenesis inhibitor therapies
Duh M, Fournier A, Moyneur E, Dial E, Neary M, Oh W. Dosing and switching patterns for renal cell carcinoma (RCC) patients receiving selected angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 5111-5111. DOI: 10.1200/jco.2008.26.15_suppl.5111.Peer-Reviewed Original ResearchFrequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies
Dial E, Fournier A, Moyneur E, Neary M, Duh M, Oh W. Frequency and cost of adverse events in renal cell carcinoma (RCC) patients receiving angiogenesis inhibitor therapies. Journal Of Clinical Oncology 2008, 26: 14609-14609. DOI: 10.1200/jco.2008.26.15_suppl.14609.Peer-Reviewed Original ResearchRenal cell carcinomaAngiogenesis inhibitor therapyCosts of adverse eventsInhibitor therapyCell carcinomaTreatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC)
Brick A, McDermott D, Clement J, Kwabi C, Shah K, Weiner J, Duh M, Neary M, Oh W, Choueiri T. Treatment discontinuations, dose reductions, and interruptions for angiogenesis inhibitor therapies in patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2008, 26: 14636-14636. DOI: 10.1200/jco.2008.26.15_suppl.14636.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply